WA-SPIE
8.2.2024 22:02:36 CET | Business Wire | Press release
SPIE, the international society for optics and photonics, held an impactful and vibrant Photonics West last week at San Francisco’s Moscone Center, with 24,000-plus technical professionals registered from more than 70 countries across the international optics and photonics community. The largest annual photonics conference, which ran from 27 January to 1 February, hosted over 1,500 exhibitors, and featured over 5,000 technical presentations across an interactive and engaging week that included BiOS, LASE, OPTO, Quantum West, the BiOS Expo, the Photonics West exhibition, the Quantum West Expo, and the co-located AR|VR|MR conference and exhibition.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240208158413/en/
SPIE Photonics West 2024 hosted an enthusiastic crowd of optics and photonics professionals at San Francisco's Moscone Center. (Photo: Business Wire)
“Photonics West heralds the beginning of the optics and photonics calendar each year for good reason,” said SPIE CEO Kent Rochford. “The invigorating energy and high levels of enthusiasm throughout the Moscone Center characterized a truly exciting week. AR|VR|MR continues to grow by leaps and bounds, and the addition of a standalone exhibit to the Quantum West program reflects the growing impact of the technology. We were also delighted by the success of our brand-new SPIE Global Business Forum, a packed event that drew top industry executives together for high-level presentations and conversation. Altogether it was a pleasure to be part of the networking, research-sharing, and collaborative discussions among world-leading scientists, engineers, students, and businesspeople and I’m already looking forward to Photonics West 2025.”
As always, the dynamic week showcased the latest innovative technologies and discoveries stemming from a diverse and thriving optics and photonics community, bringing together researchers, innovators, engineers, entrepreneurs, and business leaders from across the globe. Over 100 distinct technical conferences paired perfectly with the four exhibitions held during the week, bringing researchers and companies together to further science, technology, and applications. The week also included a wide range of live product demonstrations on the exhibition floors as well as a job fair.
The inaugural SPIE Global Business Forum was a resounding, sold-out success. With the 16th annual Prism Awards honoring the top new optics and photonics products, and the fast-paced Startup Challenge pitch competition, SPIE Photonics West recognized the best optics and photonics technologies, trends, and entrepreneurial opportunities, while the Quantum West Business Summit featured talks and panels that provided key insights into that expanding commercial ecosystem.
In addition, a program of 56 educational courses offered expert-led technical training and learning, which complemented the dozens of professional development and networking sessions. From Lunch and Learn programming focused on EDI, to networking and social events that provided many opportunities for in-person conversations and possible future collaborations, Photonics West featured a packed calendar of special events.
While the week held myriad opportunities for attendees to learn, network, and share their latest advancements, it was the buzzing exhibitions that best showcased the increasingly vital photonics industry and the importance of in-person meetings.
“The Global Business Forum made it clear that the optics and photonics industry is in the midst of a remarkable era of growth and innovation,” said Stratos Kehayas, PhD, Chief Product & Technology Officer, G&H. “The industry's collective enthusiasm at Photonics West underscores the pivotal role this trade show plays in driving collaboration, fostering innovation, and shaping the future.”
"This has been arguably one of the most productive Photonics Wests we've had in the last five years,” said nLIGHT Vice President and General Manager, Semiconductor Lasers, Matthew Randall. “It’s been very engaging, with lots of people coming through, and we're seeing new things at our booth and at other booths that make this particular show a positive experience. We are definitely seeing way more innovation now than in the last couple of years and that's been incredibly positive not only for nLIGHT, but for the entire photonics industry.”
“The week has been very good,” said MKS Instruments Senior Director of Marketing, Photonics Solutions Division, Vincent M. Issier. “The traffic has been very high and the attendance is incredible this year, and we are very happy with the level of engagement from people here.”
“The week has been great,” said IPG Photonics Director of Product Management, Beam Delivery, UV, Green & Ultrafast Lasers, Mustafa Coskun. “There was nice traffic coming through and it was really nice to connect with colleagues as well as our customers and other visitors. And this is what we're here for: to listen to our customers and understand what their problems are and how we can help them. This Photonics West has been great.”
“This year we were quite busy, even just walking around the show with so many people we know here and so many companies we are in touch with,” said TNO Business Consultant, Optics Manufacturing, Bart Snijders. “It’s great to see them all again. We’ve enjoyed being busy on the floor, busy with meetings. I would always like the show to be six or nine days long, because time is always too short for me here.”
During the Photonics West week, SPIE also announced its latest partnership – this one with The University of Manchester – in the SPIE Endowment Matching Program.
SPIE Photonics West 2025 will take place 25-30 January at the Moscone Center in San Francisco. The call for papers for the 2025 event will open in Spring of 2024.
About SPIE
SPIE, the international society for optics and photonics, brings engineers, scientists, students, and business professionals together to advance light-based science and technology. The Society, founded in 1955, connects and engages with our global constituency through industry-leading conferences and exhibitions; publications of conference proceedings, books, and journals in the SPIE Digital Library; and career-building opportunities. Over the past five years, SPIE has contributed more than $24 million to the international optics community through our advocacy and support, including scholarships, educational resources, travel grants, endowed gifts, and public-policy development. www.spie.org.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240208158413/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte’s Pivotal frontMIND Trial Showed Tafasitamab (Monjuvi®/Minjuvi®) Combination Significantly Prolonged Progression-free Survival, Reducing the Risk of Disease Progression or Death by 25% in Patients with Previously Untreated, High-risk DLBCL30.5.2026 14:00:00 CEST | Press release
The Phase 3 frontMIND study evaluated tafasitamab (Monjuvi®/Minjuvi®) and lenalidomide in addition to R-CHOP, the current standard of care, compared with R-CHOP alone in patients with previously untreated high-risk diffuse large B-cell lymphoma (DLBCL) and high-grade B-cell lymphoma (HGBL)Positive trends toward progression-free survival (PFS) benefit with tafasitamab and lenalidomide plus R-CHOP (Tafa-Len-R-CHOP) were observed acrossprespecified subgroups, including in patients with centrally confirmed lymphoma subtypes and both cell-of-origin (COO) molecular subtypesThe frontMIND data support the submission of global regulatory applications for tafasitamab and lenalidomide added to R-CHOP for previously untreated DLBCLThe data are being presented in an oral session at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting and simultaneously published in The Lancet* Incyte (Nasdaq:INCY) today announced positive results from the pivotal Phase 3 frontMIND trial evaluating t
Fortegra Completes Acquisition by DB Insurance29.5.2026 22:30:00 CEST | Press release
The Fortegra Group, Inc. ("Fortegra"), a global specialty insurance company, today announced the completion of its acquisition by DB Insurance Co., Ltd. ("DB"), one of Korea's leading property and casualty insurers. The transaction, announced on September 26, 2025, received all required regulatory and stockholder approvals. Fortegra will operate independently, maintaining its existing leadership team, distribution relationships, and underwriting discipline. Agents, distribution partners, and customers will continue to experience the service excellence that has defined the Fortegra experience. Richard Kahlbaugh, Chairman and CEO of Fortegra, said: "Every company eventually changes ownership. That is the nature of business. The closing of this acquisition is a starting point. As part of DB Insurance, Fortegra is positioned to expand our business geographically, enhance our capabilities and deepen our market presence in the US, Europe, the United Kingdom and Asia. Together, DB Insurance a
SINOVAC Receives Nasdaq Notification Regarding Late Filing of 2025 Annual Report29.5.2026 22:01:00 CEST | Press release
Sinovac Biotech Ltd. (Nasdaq: SVA) (“SINOVAC” or the “Company”), a leading provider of biopharmaceutical products in China, today announced that it received a notification letter dated May 20, 2026 (the “Notification Letter”), from Nasdaq Listing Qualifications (“Nasdaq”) stating that as of May 8, 2026, the Company had regained compliance with the periodic filing and interim financial requirements in Nasdaq Listing Rules 5250(c)(1) (the “Periodic Filing Rule”) and 5250(c)(2), as required by the Panel’s decision dated January 21, 2026. As previously disclosed on January 22, 2026, under the Panel’s decision, SINOVAC was required to, on or before May 11, 2026, demonstrate compliance with such Nasdaq Listing Rules by completing filings of its annual report for the year ended December 31, 2024, on Form 20-F and an interim balance sheet and income statement as of the end of its second quarter of 2025 on Form 6-K. The Company timely completed such filings as required by the Panel’s decision.
From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 15:00:00 CEST | Press release
Newest expansion of the NetBrain platform delivers Agent Skills, AI Path Doctor, MCP Server, and expanded cross-domain integrations, extending the agentic capabilities already running in production at hundreds of enterprises. NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under
Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 14:00:00 CEST | Press release
News summary: Non-practicing entity litigation continues to create costly, time-consuming pressure across the technology industry Adtran has reached a full settlement following counterclaims, with payment made to Adtran and all claims dismissed with prejudice Outcome reflects Adtran’s commitment to defend its innovations, customers and business against meritless patent assertions Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
